

# Package: asaur (via r-universe)

September 16, 2024

**Type** Package

**Title** Data Sets for ``Applied Survival Analysis Using R''

**Version** 0.50

**LazyData** true

**Date** 2016-04-10

**Author** Dirk F. Moore

**Description** Data sets are referred to in the text ``Applied Survival Analysis Using R'' by Dirk F. Moore, Springer, 2016, ISBN: 978-3-319-31243-9, <DOI:10.1007/978-3-319-31245-3>.

**Maintainer** Dirk F. Moore <dirkmoore@gmail.com>

**License** CC0

**NeedsCompilation** no

**Date/Publication** 2016-04-12 06:23:05

**Repository** <https://mooredf22.r-universe.dev>

**RemoteUrl** <https://github.com/cran/asaur>

**RemoteRef** HEAD

**RemoteSha** 0d782825331f15a729be9f999faec7e13180bc06

## Contents

ashkenazi . . . . .	2
ChanningHouse . . . . .	2
gastricXelox . . . . .	4
hepatoCellular . . . . .	4
pancreatic . . . . .	6
pancreatic2 . . . . .	7
pharmacoSmoking . . . . .	8
prostateSurvival . . . . .	9

<b>Index</b>	<b>10</b>
--------------	-----------

ashkenazi

*ashkenazi*

---

**Description**

This is a random subset of data from the Struewing et al. (1997) study of Ashkenazi jews and breast cancer. The subset consists of pairs of first-degree female relatives who are also first degree relatives of a proband.

**Usage**

```
data("ashkenazi")
```

**Format**

A data frame with 3920 observations on the following 4 variables.

famID family ID indicator

brcancer 1 if subject had breast cancer, 0 if not

age Age at onset of breast cancer, or current age if no breast cancer

mutant 1 if first degree relative proband was a BRCA mutation carrier, 0 if not

**References**

Moore DF, Chatterjee N, Pee D, and Gail MH (2001) Pseudo-likelihood estimates of the cumulative risk of an autosomal dominant disease from a kin-cohort study. *Genetic Epidemiology* 20, 210-227.)

Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, and Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among ashkenazi jews. *New England Journal of Medicine* 336, 1401-1408.)

**Examples**

```
data(ashkenazi)
```

**Description**

The ChanningHouse data frame has 457 rows and 5 columns. This is 5 fewer than the parent channing data frame in the boot package. These 5 were removed because the exit time was not smaller than the entry time.

Channing House is a retirement centre in Palo Alto, California. These data were collected between the opening of the house in 1964 until July 1, 1975. In that time 97 men and 365 women passed through the centre. For each of these, their age on entry and also on leaving or death was recorded. A large number of the observations were censored mainly due to the resident being alive on July 1, 1975 when the data was collected. Over the time of the study 130 women and 46 men died at Channing House. Differences between the survival of the sexes, taking age into account, was one of the primary concerns of this study.

**Usage**

```
data("ChanningHouse")
```

**Format**

A data frame with 457 observations on the following 5 variables.

`sex` a factor for the sex of each resident with levels Female Male

`entry` The residents age (in months) on entry to the center)

`exit` The age (in months) of the resident on death, leaving the center or July 1, 1975, whichever event occurred first.)

`time` The length of time (in months) that the resident spent at Channing House. (`time=exit-entry`))

`cens` The indicator of reight censoring. 1 indicates that the resident died at Channing House, 0 indicates that they left the house prior to July 1, 1975 or that they were still alive and living in the center at that date.

**Source**

The current data were derived from the "channing" data frame in the "boot" package. The original source for the data was

Hyde, J. (1980) Testing survival with incomplete observations. Biostatistics Casebook. R.G. Miller, B. Efron, B.W. Brown and L.E. Moses (editors), 31-46. John Wiley.

**References**

Davison, A.C. and Hinkley, D.V. (1997) Bootstrap Methods and Their Application. Cambridge University Press.

Canty, A. and Ripley, B. (2015) boot package.

**Examples**

```
data(ChanningHouse)
```

---

gastricXelox

*gasticXelox*

---

### Description

Data from a Phase II clinical trial of Xeloda and oxaliplatin given before surgery to advanced gastric cancer patients with para-aortic lymph node metastasis.

### Usage

```
data("gastricXelox")
```

### Format

A data frame with 48 observations on the following 2 variables.

timeWeeks survival time in weeks

delta 1 for death, 0 for censored

### Details

The data were extracted from the Kaplan-Meier survival plot.

### References

Wang Y, Yu Y-Y, Li W, Feng Y, Hou J, Ji Y, Sun Y-H, Shen K-T, Shen Z-B, Qin X-Y, and Liu T-S. (2014) A phase II trial of xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. *Cancer Chemotherapy and Pharmacology* 73(6), 1155-1161.)

### Examples

```
data(gastricXelox)
```

---

hepatoCellular

*hepatoCellular*

---

### Description

Overall and recurrence-free survival of patients with hepatocellular carcinoma.

### Usage

```
data("hepatoCellular")
```

**Format**

A data frame with 227 observations on 48 clinical and biomarker variables

Number Patient ID number

Age a numeric vector

Gender a numeric vector

HBsAg a numeric vector

Cirrhosis a numeric vector

ALT a numeric vector

AST a numeric vector

AFP a numeric vector

Tumorsize a numeric vector

Tumordifferentiation a numeric vector

Vascularinvasion a numeric vector

Tumormultiplicity a numeric vector

Capsulation a numeric vector

TNM a numeric vector

BCLC a numeric vector

OS Overall survival

Death 1 denotes death, 0 censored

RFS Recurrence-free survival

Recurrence 1 denotes recurrence, 0 censored

CXCL17T a numeric vector

CXCL17P a numeric vector

CXCL17N a numeric vector

CD4T a numeric vector

CD4N a numeric vector

CD8T a numeric vector

CD8N a numeric vector

CD20T a numeric vector

CD20N a numeric vector

CD57T a numeric vector

CD57N a numeric vector

CD15T a numeric vector

CD15N a numeric vector

CD68T a numeric vector

CD68N a numeric vector

CD4NR a numeric vector

CD8NR a numeric vector  
CD20NR a numeric vector  
CD57NR a numeric vector  
CD15NR a numeric vector  
CD68NR a numeric vector  
CD4TR a numeric vector  
CD8TR a numeric vector  
CD20TR a numeric vector  
CD57TR a numeric vector  
CD15TR a numeric vector  
CD68TR a numeric vector  
Ki67 a numeric vector  
CD34 a numeric vector

## References

Li L, Yan J, Xu J, Liu C-Q, Zhen Z-J, Chen H-W, Ji Y, Wu Z-P, Hu J-Y, Zheng L, Lau WY (2014) Cxcl17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma. Plos One 9 (10) e110064.

Li L, Yan J, Xu J, Liu C-Q, Zhen Z-J, Chen H-W, Ji Y, Wu Z-P, Hu J-Y, Zheng L, Lau WY (2014) Cxcl17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma. Dryad Digital Repository datadryad.org.

## Examples

```
data(hepatoCellular)
```

---

pancreatic

*pancreatic*

---

## Description

Data from a Phase II clinical trial of patients with locally advanced or metastatic pancreatic cancer.

## Usage

```
data("pancreatic")
```

**Format**

A data frame with 41 observations on the following 4 variables.

stage a factor with levels LA (locally advanced) or M (metastatic)

onstudy date of enrollment into the clinical trial, in month/day/year format

progression date of progression, in month/day/year format

death date of death, in month/day/year format

**Details**

Since all patients in this study have known death dates, there is no censoring.

**References**

Moss RA, Moore D, Mulcahy MF, Nahum K, Saraiya B, Eddy S, Kleber M, and Poplin EA (2012) A multi-institutional phase 2 study of imatinib mesylate and gemcitabine for first-line treatment of advanced pancreatic cancer. *Gastrointestinal Cancer Research* 5, 77 - 83.

**Examples**

```
data(pancreatic)
```

---

pancreatic2

*pancreatic2*

---

**Description**

This is the same data as in 'pancreatic', with overall and progression-free survival calculated. Dates have been removed.

**Usage**

```
data("pancreatic2")
```

**Format**

A data frame with 41 observations on the following 4 variables.

pfs Progression-free survival: Time from entry until disease progression. If no progression was observed, before death, the time to death is used.

os Overall survival: Time from entry until death

status This censoring indicator is 1 for all patients, since all patients died.

stage a factor with levels LA (locally advanced) or M (metastatic)

**References**

Moss RA, Moore D, Mulcahy MF, Nahum K, Saraiya B, Eddy S, Kleber M, and Poplin EA (2012) A multi-institutional phase 2 study of imatinib mesylate and gemcitabine for first-line treatment of advanced pancreatic cancer. *Gastrointestinal Cancer Research* 5, 77 - 83.

**Examples**

```
data(pancreatic2)
```

---

pharmacoSmoking	<i>pharmacoSmoking</i>
-----------------	------------------------

---

**Description**

Randomized trial of triple therapy vs. patch for smoking cessation.

**Usage**

```
data("pharmacoSmoking")
```

**Format**

A data frame with 125 observations on the following 14 variables.

id patient ID number  
 ttr Time in days until relapse  
 relapse Indicator of relapse (return to smoking)  
 grp Randomly assigned treatment group with levels combination or patchOnly  
 age Age in years at time of randomization  
 gender Female or Male  
 race black, hispanic, white, or other  
 employment ft (full-time), pt (part-time), or other  
 yearsSmoking Number of years the patient had been a smoker  
 levelSmoking heavy or light  
 ageGroup2 Age group with levels 21-49 or 50+  
 ageGroup4 Age group with levels 21-34, 35-49, 50-64, or 65+  
 priorAttempts The number of prior attempts to quit smoking  
 longestNoSmoke The longest period of time, in days, that the patient has previously gone without smoking

**Source**

This data is from a clinical trial described in Steinberg et al. (2009)



**References**

Steinberg, M.B. Greenhaus, S. Schmelzer, A.C. Bover, M.T., Foulds, J., Hoover, D.R., and Carson, J.L. (2009) Triple-combination pharmacotherapy for medically ill smokers: A randomized trial. *Annals of Internal Medicine* 150, 447-454.

**Examples**

```
data(pharmacoSmoking)
```

---

```
prostateSurvival      prostateSurvival
```

---

**Description**

This data set contains survival times for two competing causes: time from prostate cancer diagnosis to death from prostate cancer, and time from prostate cancer diagnosis to death from other causes. The data set also contains information on several risk factors. The data in this data set are simulated from detailed competing risk survival curves and counts of numbers of patients per group presented in Lu-Yao et al. (2009). Thus, the simulated data presented here contain many of the characteristics of the original SEER-Medicare prostate cancer data used in Lu-Yao et al. (2009).

**Usage**

```
data("prostateSurvival")
```

**Format**

A data frame with 14294 observations on the following 5 variables.

`grade` a factor with levels `moderate` (moderately differentiated) and `poor` (poorly differentiated)  
`stage` a factor with levels `T1ab` (Stage T1, clinically diagnosed), `T1c` (Stage T1, diagnosed via a PSA test), and `T2` (Stage T2)  
`ageGroup` a factor with levels `66-69` `70-74` `75-79` `80+`  
`survTime` time from diagnosis to death or last date known alive  
`status` a censoring variable, 0, (censored), 1 (death from prostate cancer), and 2 (death from other causes)

**Source**

Lu-Yao, GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao S-L (2009) Outcomes of localized prostate cancer following conservative management. *Journal of the American Medical Association* 302, 1202 - 1209.)

**Examples**

```
data(prostateSurvival)
```

# Index

## \* datasets

- ashkenazi, [2](#)
- ChanningHouse, [2](#)
- gastricXelox, [4](#)
- hepatoCellular, [4](#)
- pancreatic, [6](#)
- pancreatic2, [7](#)
- pharmacoSmoking, [8](#)
- prostateSurvival, [9](#)

ashkenazi, [2](#)

ChanningHouse, [2](#)

gastricXelox, [4](#)

hepatoCellular, [4](#)

pancreatic, [6](#)

pancreatic2, [7](#)

pharmacoSmoking, [8](#)

prostateSurvival, [9](#)